| http://www.w3.org/ns/prov#value | - There is evidence that both lenalidomide79 and the inhibitor of Bruton???s tyrosine kinase ibrutinib80 are active in ABC-type DLBCL. Several groups are exploring R-CHOP in combination with lenalidomide (R2-CHOP)81??????-84 and ibrutinib in nodal DLBCL. The data available so far suggest that these combinations are well tolerated and effective, although to the best of our knowledge, patients with PT
|
